Aisling Capital, Others Inject $48M Into Roka Bioscience

Law360, New York (January 6, 2012, 5:19 PM EST) -- Life science private equity firm Aisling Capital joined OrbiMed Advisors LLC, New Enterprise Associates Inc. and Tarrant Capital IP LLC in issuing $47.5 million in Series D financing for molecular testing technology company Roka Bioscience, the company announced Friday.

Roka closed on $27.5 million of the financing in December and expects to complete the round later this year, bringing the company's total amount raised to $104.7 million since its founding in September 2009.

The terms of the financing were not disclosed.

“We are very pleased with...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.